ArticleNuclear medicine and molecular imaging2025
FDG-PET Image Classification in Alzheimer's Disease: from Traditional Visual Analysis to Advanced Transfer Learning.
Article in Nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Brain PET in the era of anti-amyloid-β antibody therapy for Alzheimer disease.Japanese journal of radiology · 2026Review
- Hypertension is the Main Vascular Risk Factor for Cognitive Impairment, Microvascular Pathology and Brain Atrophy in Alzheimer's Disease.Current Alzheimer research · 2026Article
- Pathological mechanisms and treatment progression of Alzheimer's disease.European journal of medical research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Alzheimer's disease (AD) often coexists with other brain pathologies, and we aimed to classify people with AD using 18 F- Flouro-Deoxy-Glucose-Positron Emission Tomography (FDG-PET). Method: Baseline FDG-PET data were collected as part of two large scale Phase III clinical trials of a novel tau aggregation inhibitor drug, Leuco-Methylthioninium (LMTX®). A total of 794, well-characterised probable AD subjects were included in the study and the images were classified into "typical AD"(temporoparietal hypometabolism) and "mixed" (patchy hypo-metabolism in other vascular territories of brain such as frontal and cerebellar regions along with temporo-parietal hypo-metabolism) patterns based on visual interpretation. The differences in the two groups were further assessed with region-of-interest based analysis of Standardized Uptake Value Ratio (SUVR) and automated classification using transfer learning with visual classification as the gold standard. Results: Of the total of 794 (438 female) participants, 533 (284 female) were classified as typical AD and 261 (154 female) participants classified as mixed. A subset of 50 images each from typical and mixed subtypes were used for transfer learning and sensitivity, specificity and accuracy for one of the cross-validation loops was 94.73%, 95.23% and 95% respectively. The average accuracy to distinguish the two subtypes after 5-fold cross validation was found to be 97.5%. Conclusions: This study is first of its kind to distinguish two subtypes of AD through visual interpretation of FDG-PET images and exploring the findings with a semi-quantitative method followed by transfer learning, which has been used to predict the two subtypes with high accuracy, sensitivity and specificity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.